ISRCTN94991276终止未知
Circulating tumour DNA guidEd Therapy for stage IIB/C mElanoma after surgiCal resecTION (DETECTION)
Christie Hospital NHS Foundation Trust0 个研究点目标入组 8 人开始时间: 2021年8月17日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 终止
- 发起方
- 入组人数
- 8
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Signed written informed consent
- •2. Patients must be willing and able to comply with scheduled visits, treatment schedule, laboratory tests and other requirements of the study
- •3. Histological confirmation of cutaneous melanoma
- •4. Age =18 years
- •5. Stage IIB or IIC melanoma (sentinel lymph node (SNLB) staged) according to AJCC version 8 (4)
- •6. Complete resection (including SNLB) must have been performed within 12 weeks prior to registration
- •7. Disease-free status documented both clinically and radiologically within 4 weeks prior to registration
- •8. Mutation confirmed in at least one of the following BRAF (p.V600E/p.V600K/p.V600R) /NRAS (p.Q61R/p.Q61K, p.Q61L/p.G12D), which can be tracked in ctDNA with exact point mutation known
- •9. ECOG performance status 0/1
- •10. Adequate organ function and screening laboratory values must meet the following criteria: WBC = 2.0x109/L, Absolute neutrophil count (ANC) =1.5x10?/l, Platelets =100 x10?/l, Haemoglobin =90 g/l, Creatinine =1.5 x ULN or creatinine clearance >30 ml/min using Cockcroft-Gault, AST =1.5 x ULN, ALT =1.5 x ULN, Bilirubin =1.5 x ULN unless the patient has familial hyperbilirubinaemia
- •11. LDH =1.5 x ULN as per local institution parameters
- •12. Patients who are pregnant or breastfeeding will be eligible to join the trial. However, if they are allocated to Arm B, women of childbearing potential (WOCBP) must agree to have a serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) and must be withdrawn if pregnant or breastfeeding. WOCBP and males who are sexually active with WOCBP must also agree to follow instructions for method(s) of contraception for the duration of treatment plus 5 months if randomised to Arm B (or while receiving any systemic treatment and to follow local guidance if given on Arm A).
排除标准
- •1. If previously received prior immunotherapy, chemotherapy, cancer directed vaccine therapy or BRAF/MEK targeted therapy for cancer
- •2. Patients with active, known or suspected autoimmune disease. Patients with type 1 diabetes mellitus, rheumatoid arthritis not requiring disease modifying drugs, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger will be permitted to enrol.
- •3. Current other malignancy or history of another malignancy within the last 3 years. Patients who have been disease-free for 3 years, (i.e. patients with second malignancies that have been definitively treated at least 3 years ago) or patients with a history of completely resected non-melanoma skin cancer are eligible
- •4. Any serious or unstable pre-existing medical conditions (aside from malignancy exceptions specified above), psychiatric disorders, or other conditions that could interfere with the patient’s safety, obtaining informed consent, or compliance with study procedures
- •5. Patients with a condition requiring ongoing/long-term (> 3 months) systemic treatment with either corticosteroids (>10 mg daily prednisone equivalent) or other immunosuppressive medications. Inhaled or topical steroids and adrenal replacement steroid doses =10 mg daily prednisolone equivalent are permitted in the absence of active autoimmune disease
- •6. Patients with interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity
- •7. History of allergies or adverse drug reaction to any of the study drug components or to any monoclonal antibody
- •8. Known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection
- •9. Prisoners or patients who are involuntarily incarcerated
研究者
相似试验
招募中
不适用
Circulating tumor DNA based adjuvant chemotherapy in stage II colon cancer patients: the MEDOCC-CrEATE trialNL-OMON54658niversitair Medisch Centrum Utrecht1,320
进行中（未招募）
2 期
DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)Breast CancerNCT04567420Criterium, Inc.70
进行中（未招募）
1 期
Circulating tumour DNA based decision for adjuvant treatment in colon cancer stage II evaluation (CIRCULATE) AIO-KRK-0217Colon cancer stage IIMedDRA version: 21.0Level: PTClassification code 10009954Term: Colon cancer stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10038049Term: Rectal cancer stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-003691-12-DETechnische Universität Dresden4,812
招募中
3 期
Circulating tumour DNA based decision for adjuvant treatment in colon cancer stage II evaluation (CIRCULATE), AIO-KRK-0217DRKS00018695Technische Universität Dresden4,812
招募中
1 期
CIRCULATEcolon cancer stage II, rectal cancer stage IIMedDRA version: 21.0Level: PTClassification code: 10009954Term: Colon cancer stage II Class: 100000004864MedDRA version: 21.0Level: PTClassification code: 10038049Term: Rectal cancer stage II Class: 100000004864CTIS2023-506715-18-00Technische Universitat Dresden140